Serum KL-6 as a biomarker for interstitial lung diseases in a clinical setting: application of a fully automated immunoassay

Bonella, Francesco; Hegedues, Balasz; Langer, Sandra; Honshoven, Fanny; Gottstein, Eva; Theegarten, Dirk; Costabel, Ulrich

doi:10.1183/13993003.congress-2019.pa4697

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The patient cohort was small and data were collected only at one ILD center. The control group consisted of healthy individuals that were not age-/sex-matched to the study population even though there is no evidence to support differences with regards to age or gender [46]. Differences in KL-6 level changes between the patients with different treatment regimens must be cautiously interpreted due to small patient numbers.…”

Section: Kl-6 As a Potential Predictive Biomarker In Fildmentioning

confidence: 99%

Krebs von den Lungen-6 as a Potential Predictive Biomarker in Fibrosing Interstitial Lung Diseases

Lederer,

Mayer,

Somogyi

et al. 2023

Respiration

View full text Add to dashboard Cite

Background: As fibrosing interstitial lung diseases (fILDs) are associated with high mortality, monitoring of disease activity under treatment is highly relevant. Krebs von den Lungen-6 (KL-6) is associated with the presence and severity of different fILDs, mainly in Asian patient populations. Objectives: Our aim was to evaluate KL-6 as a predictive biomarker in fILDs in Caucasian patients. Methods: Consecutive patients with fILDs were recruited prospectively and serum concentrations of KL-6 were measured at baseline (BL), after 6 and 12 months (6 Months, 12 Months). Clinical characteristics including pulmonary function tests were assessed at 6-monthly visits and correlated with KL-6 BL levels as well as with KL-6 level changes. Results: A total of 47 fILD patients were included (mean age: 65 years, 68% male). KL-6 levels at BL were significantly higher in fILD patients than in healthy controls (n = 44, mean age: 45, 23% male) (ILD: 1,757 ± 1960 U/mL vs. control: 265 ± 107 U/mL, p < 0.0001). However, no differences were noted between ILD subgroups. KL-6 decreased significantly under therapy (6M∆BL-KL6: −486 ± 1,505 mean U/mL, p = 0.032; 12M∆BL-KL6: −547 ± 1,782 mean U/mL, p = 0.041) and KL-6 level changes were negatively correlated with changes in pulmonary function parameters (forced vital capacity [FVC]: r = −0.562, p < 0.0001; DLCOSB: r = −0.405, p = 0.013). While neither absolute KL-6 levels at BL nor KL-6 level changes were associated with ILD progression (FVC decline ≥10%, DLCOSB decline ≥15% or death), patients with a stable FVC showed significantly decreasing KL-6 levels (p = 0.022). Conclusions: A decline of KL-6 under therapy correlated with a clinically relevant stabilization of lung function. Thus, KL-6 might serve as a predictive biomarker, which however must be determined by larger prospective cohorts.

show abstract

Section: Kl-6 As a Potential Predictive Biomarker In Fildmentioning

confidence: 99%